Nightingale Health Plc
Stock exchange release
12 March 2025 at 2:30 p.m. (EET)

Nightingale Health Plc (“Nightingale Health” or the “Company”) has today submitted a listing application with Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) to admit the Company’s series B shares (the “Shares”) on trading on the Main Market of Nasdaq Helsinki (the “Listing”). The Listing is conditional upon Nasdaq Helsinki approving the Company’s listing application and the Finnish Financial Supervisory Authority approving the prospectus prepared in connection with the Listing.

Trading in the Shares is expected to commence on the Main Market of Nasdaq Helsinki on or about 19 March 2025. In addition, the Company has requested the Shares to be removed from the First North Growth Market Finland marketplace maintained by Nasdaq Helsinki.

The aim of the contemplated Listing is to improve the liquidity of the Shares and to achieve a broader international shareholder base.

“Since listing on First North on 19 March 2021, Nightingale Health’s growth story has taken major steps forward. In January last year, we achieved a breakthrough when our advanced disease risk detection technology for chronic diseases was adopted in nation-wide preventative healthcare in Finland. The next chapter in our story has already started and our technology is being adopted rapidly in new countries, including Singapore and the United States. We continue to work towards our mission to make preventative healthcare a global standard for tackling the pressing problem of chronic diseases”, says Teemu Suna, CEO and Founder of Nightingale Health. “As we expand our business internationally, we also want to enable that more international investors can join the growth story. We believe that transferring to the Main Market supports this goal.”

The trading code of the Shares, HEALTH, and the ISIN code, FI4000490875, will remain unchanged. As of today, Nightingale Health complies with the regulations on the disclosure obligations of companies listed on a regulated market.

Borenius Attorneys Ltd acts as the Company’s legal advisor in connection with the Listing. 

 

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

 

Certified advisor:

Oaklins Finland Ltd, tel. +358 9 6129 670

 

About Nightingale Health

Nightingale Health has developed the world’s most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

 

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. Read more: https://nightingalehealth.com/